CytoSorbents Corporation

CytoSorbents Corporation is a medical device company based in Princeton, New Jersey, with 169 employees. The company generated $41.3 million in revenue. CytoSorbents specializes in the research, development, and commercialization of medical devices utilizing its patented polymer adsorption technology. CytoSorbents focuses on treating life-threatening conditions within intensive care units (ICUs) and cardiac surgery settings using blood purification techniques. Their leading product, CytoSorb®, is available in over 70 countries and holds CE Mark approval in the European Union for various critical care applications, including the removal of cytokines, bilirubin, myoglobin, and antithrombotic medications like ticagrelor and rivaroxaban during cardiothoracic surgery. The company is actively pursuing multiple clinical trials, including two pivotal randomized controlled trials in the United States focused on obtaining FDA marketing approval for the DrugSorb™-ATR Antithrombotic Removal System, aimed at removing antithrombotic medications during cardiothoracic surgery. For more information about CytoSorbents Corporation, visit their website at cytosorbents.com.